Non-immunogenic Staphylokinase in Reperfusion Therapy of Ischemic Stroke in Routine Clinical Practice

National Society for Neurosonology and Cerebral Circulation336 enrolled

Overview

The study will collect data from aged 18 to 85 years with a diagnosis of acute stroke, who received thrombolytic treatment with a new agent, nonimmunogenic staphylokinase. Outcomes will be checked for safety and compared to the results of treatment with the other thrombolytic drug, alteplase.

Study Type

OBSERVATIONAL

Enrollment

336

Conditions

Acute Stroke

Eligibility

Sex: ALLMin age: 18 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age 18-85 ; * Diagnosis of acute ischemic stroke eligible for thrombolytic therapy; * Thrombolytic therapy with the drug "non-immunogenic staphylokinase" is planned or has already been performed. Exclusion Criteria: * Individual intolerance or known hypersensitivity to a recombinant protein containing the amino acid sequence of staphylokinase; * The presence of a contraindication to thrombolytic therapy of ischemic stroke; * Pregnancy or lactation.

Locations (1)

St. Petersburg Research Institute of Emergency Medicine named after I.I. Janelidze

Saint Petersburg, Russia

RECRUITING

Outcomes

Primary Outcomes

Proportion of intracerebral hemorrhage

Number and proportion of intracerebral bleeding of any type, which occurs as a complication of thrombolytic treatment

Time frame: 36 hours

Central Contacts

Tatiana Kharitonova

CONTACT

+79217450431 tvh2001@mail.ru

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.